The Ronapreve, the Roche Laboratory, and the Regdanvimab, South Korean Celltrion, have received, Thursday, their authorization to put on the European market.
Le Monde with AFP
The European regulator said, Thursday, November 11, having approved for the first time the marketing in the European Union of two antibody treatments against coronavirus.
The European Medicines Agency has indicated, In a communiqué , have approved the use of a treatment of the Swiss Pharmaceutical Laboratory Rock, the Ronapreve (known antibody cocktail In the United States as Regen-VOCs), and a treatment of the South Korean society Celletrion, the Regdanvimab.
The European Commissioner for Health, Stella Kyriakides, said that the approval of the two drugs was an “important step” against the disease, the EU so far based on four vaccines. “With increases in CVIV-19 contamination in almost all Member States, it is reassuring to see many promising development developments as part of our therapeutic strategy against CVIV-19,” she added in a communicated. Today, we are taking an important step towards our goal of authorizing up to five new treatments in the EU by the end of the year. “
This decision occurred after Eli Lilly withdrew his request for approval by the EU of his antibody-based treatment, the pharmaceutical group quoting a too small demand from the Member States. Other suppliers.
Antibodies are one of the bases of our immune system. Faced with the presence of a dangerous element, such as a virus, our body naturally produces to spot the invader. The synthetic antibodies make it possible to select natural antibodies and to reproduce them artificially to then administer them in treatment, usually by an infusion.